V. Antona
Novartis (Switzerland)(CH)Novartis Institutes for BioMedical Research
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management, Cancer Immunotherapy and Biomarkers, Computational Drug Discovery Methods, HER2/EGFR in Cancer Research
Most-Cited Works
- → Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer(2018)22 cited
- → Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advancedNRAS- orBRAF-mutated melanoma(2019)20 cited
- → Overall Survival and Biomarker Results from a Phase 2 Study of Mek1/2 Inhibitor Binimetinib (Mek162) in Patients with Advanced Nras-Mutant Melanoma(2014)17 cited
- → 3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma(2015)10 cited
- → The Value of Archaeological Heritage: An Analysis by the Professional Association of Spanish Archaeologists (APAE)(1995)7 cited